GUTS FRACTYL HEALTH INC

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at . The webcast will be archived and available for replay following the live event.

About Fractyl Health        

Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Contact 

Brian Luque, Head of Investor Relations and Corporate Development

, 951.206.1200



EN
17/03/2026

Underlying

GUTSFRACTYL HEALTH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FRACTYL HEALTH INC

 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Res...

Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports new post-hoc analyses from REMAIN-1 Midpoint Cohort showing statistically significant ablation-length (i.e., dose)-dependent treatment effect on post-GLP-1 weight maintenance at 6 months Patients with greater GLP-1-induced weight loss prior to randomization also exhibited larger ...

18h / 4m 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial R...

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed...

March 17, 2026 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of R...

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anticipated pivotal data readout BURLINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today ann...

February 26, 2026 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoi...

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita’s potential to be the first d...

January 29, 2026 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to...

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the C...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch